CN102802442B - Prenatal milk-derived composition for preventing the risk of low birthweight of newborns - Google Patents
Prenatal milk-derived composition for preventing the risk of low birthweight of newborns Download PDFInfo
- Publication number
- CN102802442B CN102802442B CN201080026600.5A CN201080026600A CN102802442B CN 102802442 B CN102802442 B CN 102802442B CN 201080026600 A CN201080026600 A CN 201080026600A CN 102802442 B CN102802442 B CN 102802442B
- Authority
- CN
- China
- Prior art keywords
- milk
- cow
- birth weight
- pregnant woman
- phosphatide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pediatric Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
An object of the present invention is to develop a pharmaceutical composition or a food composition that ameliorates the low birthweight of newborns and prevents the birthweight from decreasing to a level below the average body weight (low body weight at birth) through improvement of nutrients during pregnancy. The present invention provides an agent for preventing low birthweight comprising milk phospholipids as an active ingredient, by which the low birthweight of newborns can be prevented.
Description
Technical field
The invention belongs to health food technology field, more specifically, the invention belongs to the food compositions technical field of the risk for preventing birth weight reduction.
Background technology
In Japan, until when birth in 1975 is less than or equal to 2500 grams of birth weight reduction problems improves, but since nineteen eighty, the ratio that birth weight reduces in Japanese neonate is increasing always.Reason is as follows behind.Before 1980, suggestion pregnant woman has enough nutrition to take at period of gestation, but from 1975-1980, even, in the general citizen of Japan, starts to be noted energy absorption and too much also can cause fat or various metabolic problems.Pregnant woman is warned at the nutrient excess of period of gestation and takes in, and may cause abnormal labour or cause complications of pregnancy.In addition also relate to, the requirement of pregnant woman's cosmetics.Also point out that other reasons is the variation of obstetrics' medical science theory, the increase of premature's quantity, within more than 20 year old, young woman's smoking rate increases, the impact that multifetation increases etc. (non-patent literature 1).
The connatae weight loss of neonate may with diabetes, hypertension, the disease associations such as coronary artery disease (non-patent literature 2), in addition, also disclosing this also may be relevant to metabolic syndrome.In addition, the newborn respiration function of LBW is jejune mostly, in such baby, and the 25% generation premature labor apnea of can having an appointment.There is report to point out to exist the onset risk of brain or other organ diseases.
As mentioned above, the connatae under-weight of neonate can produce various burdens, disorder or risk, so think and prevent that connatae under-weight from being important.As its countermeasure, think and importantly have good eating habit (regularly having breakfast etc.) (non-patent literature 3).In addition, the connatae infant of low-birth weight's prediction and diagnostic method are for example in the news in patent documentation 1.
It should be noted that, the gestational period nutrient such as vitamin necessity, the particularly gestational period in the absorption of folic acid be suggested more than 40 year.Think that folic acid deficiency forms relevant with inhibition central nervous system always.Before conceived, start folic acid and take in, this is because it can reduce the risk (NTD) (non-patent literature 4) of NTD.In addition, the correlation (non-patent literature 5) between pregnant woman's cobalamin or folic acid deficiency and the connatae weight loss of neonate is also disclosed.
Patent documentation 1: No. 2002-512047, Japanese Unexamined Patent Application Publication
Non-patent literature 1:http: //www.aiiku.or.jp/aiiku/jigyo/contents/kaisetsu/ks0207/ks0 207.htm
Non-patent literature 2:Lancet 1999, the 353 volumes, the 9166th phase, 1789-1792 page
Non-patent literature 3:http: //www.asagumi.jp/asagohan/txt/1-6
Non-patent literature 4:Report Concerning Reduction in the Risk of the Onset of Neural Tube Defects (December 2000) Conference concerning Risk of the Onset of Inborn Error (about reducing the report (putting down in December, 12) of NTD onset risk about the seminar of reduction birth defect occurrence risk)
Non-patent literature 5:Asia Pac Journal of Clinical Nutrition 2006, the 15 volumes, 538-543 page
Summary of the invention
The 1st problem of the present application is to develop a kind of pharmaceutical composition or food compositions, described pharmaceutical composition or food compositions are by improving pregnancy period nutrition, improve neonatal birth weight and reduce, prevent that neonatal weight from dropping to lower than neonatal weight average level (reducing also referred to as neonatal birth weight below).
In addition, the 2nd problem of the present invention is to invent a kind of pharmaceutical composition or food compositions for preventing that neonatal birth weight from reducing, described pharmaceutical composition or food compositions are towards following pregnant woman: due to using fast food as staple food and hypovitaminosis cause nutrition unbalanced, and then may cause the risk that birth weight reduces to increase (under the background condition that LBW neonate quantity increases in the recent period).
All the time, folic acid is used as period of gestation pregnant woman's prescription nutrient, and folic acid is a kind of water soluble vitamin, and known unstable to light, acid, alkali, heat etc.The beverage (such as milk etc.) that contains folic acid etc. is noted and in long term storage, observes degradation problem under folic acid concentration, for example (Nihon Chikusan Gakkaiho (Japanese animal science can be reported) 2009, the 80th volume, 41-45 page).Therefore, be desirable to provide a kind of gravidic nutrient that is different from folic acid, safety, really and the medicine having good keeping qualities or for special purposes food or the dietary supplement of gestation always.
Cow's milk phosphatide (cow's milk phosphatide or the phosphatide from cow's milk) is safe food composition, thermally-stabilised and keeping quality excellence.By taking in cow's milk phosphatide, successfully prevented birth weight reduction, pregnant woman and neonatal health have been made to very large contribution.
Present inventors etc. give and cow's milk phosphatide by the rat of B that the pregnancy period is deficient in vitamin, evaluate the impact of vitamin(e) B group on pregnant mouse, and by just postnatal young mouse body weight, body length and organ weight evaluate the impact of vitamin(e) B group on tire mouse phase tire mouse.Result, present inventor finds: for the pregnant mouse (conceived female mouse) of the category-B that is deficient in vitamin, and children mouse weight loss during birth, but, by the pregnant mouse to the category-B that is deficient in vitamin (conceived female mouse), give and cow's milk phosphatide children mouse weight loss in the time of can preventing from being born.Thereby completed the present application.
This description comprises partly or entirely the content of recording as in the description of No. 2009-143615, the Japanese patent application of the application's basis for priority and/or accompanying drawing.
The following extremely excellent effect of the present application performance: by being used as the composition (cow's milk phosphatide) of safety of food picked-up, can prevent that birth weight from reducing.And then in general, liposoluble vitamin is difficult to decompose than water soluble vitamin.Therefore, fat-soluble cow's milk phosphatide excellence aspect long-term retentivity (not decomposing).
Accompanying drawing explanation
[Fig. 1] is illustrated in gestation and within the 20th day, opens the result that abdomen takes out tire mouse and measures tire mouse quantity and body weight thereof.
The specific embodiment
The present application comprises that one prevents birth weight depressant, described in prevent that birth weight depressant from containing cow's milk phosphatide as active ingredient, by described prevent birth weight depressant can prevent birth weight reduce.The present application comprises that a kind of birth weight that reduces reduces risk agent, and described minimizing birth weight reduces risk agent and contains cow's milk phosphatide as active ingredient, reduces risk agent can reduce the risk that birth weight reduces by described minimizing birth weight.And then, the present application also comprises that one prevents birth weight depressant, describedly prevent that birth weight depressant from containing cow's milk phosphatide as active ingredient, by described, prevent that birth weight depressant from can prevent from reducing because of pregnant woman's birth weight that category-B causes that is deficient in vitamin.The present application comprises that a kind of birth weight that reduces reduces risk agent, described minimizing birth weight reduces risk agent and contains cow's milk phosphatide as active ingredient, reduces risk agent can reduce the risk that birth weight that category-B causes reduces that is deficient in vitamin because of pregnant woman by described minimizing birth weight.
In addition, the present application comprises a kind of pregnant drug thing, by to mother neonate, be pregnant woman to described pregnant drug thing, can reduce after this neonate grows up and suffer from the risk that reduces relevant diabetes, hypertension or coronary artery disease with birth weight.
1. prevent that birth weight from reducing
The food (category-B is deficient in vitamin) that absorbs the category-B that is deficient in vitamin at period of gestation very likely causes the birth weight that this pregnant woman produces to reduce.Surprisingly, the discoveries such as present inventor are deficient in vitamin the pregnant woman of food of category-B to during with cow's milk phosphatide to picked-up, can significantly suppress or prevent that birth weight from reducing.
The composition for preventing birth weight reduction of the present application contains cow's milk phosphatide as active ingredient, and comprises:
(1) prevent birth weight depressant, can prevent that birth weight from reducing;
(2) reduce birth weight and reduce risk agent, can reduce the risk that birth weight reduces;
(3) prevent birth weight depressant, can prevent from reducing because of pregnant woman's birth weight that category-B causes that is deficient in vitamin; And
(4) reduce birth weight and reduce risk agent, can reduce the risk that birth weight that category-B causes reduces that is deficient in vitamin because of pregnant woman;
The composition of 1-1. for preventing that birth weight from reducing
In the present application, as the active ingredient of the composition for preventing birth weight reduction, can enumerate cow's milk phosphatide.As cow's milk phosphatide, can enumerate and from milk, extract lipid components with ethanol etc., then with acetone, carry out the extraction of cow's milk phosphatide.
For example from the phosphatide of cow's milk, can be prepared according to disclosed known method in No. 2002-226394A, TOHKEMY.Specifically, from the phosphatide of cow's milk can according to known method [" Lipid Chemistry (lipid chemistry) (Biochemistry Experiment lecture 3) ", Japanese biochemistry association compiles, the 23rd page, the same people of Tokyo chemistry, 1974; " lipid II phospholipid (lipid II phosphatide) (neoformation chemical experiment lecture 4) ", Japan biochemistry association compiles, the 7th page, the same people of Tokyo chemistry, the whey that when prepared by cheese, the cheese that 1991], side reaction produces when prepared by cream, side reaction produces or skim milk, carry out solvent extraction or be prepared by utilizing various chromatographic processes to carry out fractionation to this extract.For example, also can be from cream, butter from the phosphatide of cow's milk or the accessory substance butter serum (butter serum) while producing cream as the composition acquisition that is insoluble to acetone (solvent).Butter serum is also applied to milk market segment, therefore can buy (for example Zelanian Tatua company system).In butter serum, contain the MFGM that a large amount of parts has phosphatide, therefore butter serum is suitable as the raw material that extracts phosphatide.
For separating phospholipids from butter serum, utilize phosphatide to be insoluble to the character of acetone.By acetone extraction repeatedly, remove the acetone soluble composition that contains neutral lipid, obtain the acetone insoluble composition containing through concentrated phosphatide.Above-mentioned acetone insoluble composition is removed to acetone through Vacuum Concentration, this concentrate is carried out after sterilization to freeze drying.To be dried thing and pulverize, obtain the phospholipid composition from cow's milk.For example can enumerate acquisition described above phospholipid composition consist of the phosphatide that contains 85% (% by weight).In phospholipid composition, there is the composition that contains the choline such as phosphatid ylcholine and sphingomyelins.
And then, as cow's milk phosphatide, also can use " cow's milk phosphatide concentrate " (to comprise about 5 % by weight choline; 85 % by weight lipids, 10 % by weight ash contents, 4 % by weight carbohydrate, and 1 % by weight moisture) or containing the dairy products " Hohoemi " (Mingzhi Dairy Co., Ltd's system) of cow's milk phosphatide.
2. pregnant drug thing
The medicine of the present application is following pregnant drug thing, that is,
(1) pregnant drug thing (preventing birth weight depressant), prevents that birth weight from reducing;
(2) pregnant drug thing (reduce birth weight and reduce risk agent), reduces birth weight and reduces risk; Or
(3) pregnant drug thing, by mother neonate, be pregnant woman to this pregnant drug thing, can reduce after this neonate grows up and suffer from the risk that reduces relevant disease with birth weight.
As the medicine of the present application, can enumerate using cow's milk phosphatide as active ingredient,
(1) pregnant drug thing (preventing birth weight depressant), prevents that birth weight from reducing;
(2) pregnant drug thing (reduce birth weight and reduce risk agent), reduces birth weight and reduces risk;
(3) pregnant drug thing, by mother neonate, be pregnant woman to this pregnant drug thing, can reduce after this neonate grows up and suffer from the risk that reduces relevant disease with birth weight.
The medicine of the present application can adopt the suitable formulations such as powder, granule, tablet, capsule and solution.When preparation, can add conventional auxiliary agent in the preparations such as excipient, adhesive, disintegrant, lubricant.As excipient, for example, comprise starch, lactose, sucrose, methylcellulose, carboxymethyl cellulose, sodium alginate, calcium monohydrogen phosphate, synthetic aluminium silicate, microcrystalline cellulose, polyvinylpyrrolidone (PVP), hydroxypropul starch (HPS) etc.In addition, as adhesive, for example, comprise the aqueous solution or their water or the ethanolic solution etc. of starch, microcrystalline cellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone (PVP), Arabic gum powder, gelatin, glucose, sucrose etc.As disintegrant, for example, comprise starch, carboxymethyl cellulose, calcium carboxymethylcellulose, microcrystalline cellulose, hydroxypropul starch, calcium phosphate etc.And then, as lubricant, for example, comprise Brazil wax, light anhydrous silicic acid, synthetic aluminium silicate, natural aluminium silicate, synthetic magnesium silicate, hydrogenated oil and fat, hydrogenated vegetable oil derivative (Sterotex HM), sesame oil, cera alba, titanium oxide, Aluminium Hydroxide gel stearic acid, calcium stearate, dolomol, talcum, calcium monohydrogen phosphate and lauryl sodium sulfate etc.
The administering mode of the medicine of 2-1 the present application
For the medicine of the present application, particularly,
(1) pregnant drug thing, prevents that birth weight from reducing;
(2) pregnant drug thing, reduces birth weight and reduces risk; Or
(3) pregnant drug thing, by mother neonate, be pregnant woman to this pregnant drug thing, can reduce after this neonate grows up and suffer from the risk that reduces relevant disease with birth weight,
Can oral or non-enteron aisle give with, can preferred oral give with.
In addition, about the oral dose of the medicine of the present application, for example, in choline, 60mg～3.5g/ days, preferably 100mg～3.5g/ days, more preferably 200mg～3.5g/ days, more preferably in the scope of 350mg～3.5g/ days.For " cow's milk phosphatide the concentrate " (choline that contains about 5 % by weight.85 % by weight lipids, 10 % by weight ash contents, 4 % by weight carbohydrate, and 1 % by weight moisture) dosage, 1.4g～75g/ days, preferably 2.4g～75g/ days, more preferably 4.8g～75g/ days, be more preferably desirable (American Journal of Clinical Nutrition (U.S.'s clinical nutriology magazine) in the scope of 7.5g～75g/ days, 2005, the 82 volumes, 111-117 page; American Journal of Clinical Nutrition (U.S.'s clinical nutriology magazine), 2006, the 83 volumes, 905-911 page; European Journal of Nutrition (European nutrition magazine), 2007, the 46 volumes, 300-306 page, Dietary Reference Intakes (dietary reference absorption), the 411st page).
In the present application, before pregnancy, start to take in the comparatively ideal of pregnant drug thing that prevents that birth weight from reducing.The preferred whole pregnancy period is at least absorbed once this pregnant drug thing, preferably in the whole pregnancy period, continues this pregnant drug thing of picked-up (for example every day).
The medicine of 2-2. the present application is given and object
The medicine of the present application can be given and all pregnant woman, and described medicine is specially (1) pregnant drug thing (preventing birth weight depressant), prevents that birth weight from reducing; (2) pregnant drug thing (reduce birth weight and reduce risk agent), reduces birth weight and reduces risk; Or (3) pregnant drug thing, by mother neonate, be pregnant woman to this pregnant drug thing, can reduce after this neonate grows up and suffer from the risk that reduces relevant disease with birth weight.The medicine of the present application is particularly suitable for nutrition and takes in unbalanced maternity dress use.Described pregnant woman's object lesson comprises avitaminous pregnant woman, and example comprises the pregnant woman of vegetarian and Vitamin B deficiency more specifically.Vitamin B deficiency refers to folic acid deficiency, Vitamin B2 deficiency, Vitamin B6 deficiency and vitamin B12 deficiency herein.
3. pregnant woman is with special purposes food or dietary supplement
Pregnant woman of the present invention with special purposes food or dietary supplement is: (1) pregnant woman, with special used food or pregnant woman's dietary supplement, prevents that birth weight from reducing; (2) pregnant woman, with special used food or pregnant woman's dietary supplement, reduces birth weight and reduces risk; Or (3) pregnant woman is with special used food or pregnant woman's dietary supplement, by mother neonate, be that pregnant woman absorbs this pregnant woman with food or pregnant woman's dietary supplement, can reduce after this neonate grows up and suffer from the risk that reduces relevant disease with birth weight.
Special purposes food or the dietary supplement of the present application contain cow's milk phosphatide as active ingredient, and can be solid shape (for example powder and granule), pasty state, any in liquid state or suspendible shape.For example, when being mixed with beverage, conventional additive in the time of also can adding sweetener, acidulant, vitamin and other synthetic beverage agent.
The special used food of the present application or dietary supplement can be made the supplement (supplement) of the appropriate dosage forms such as powder, granule, tablet, capsule or solution.
And then the special used food of the present application or dietary supplement can be made and contain the food additives of phosphatide as active ingredient, for the preparation of pregnant woman with special used food or dietary supplement.
For the intake of special used food or the dietary supplement of the present application, for example, in choline, 60mg～3.5g/ days, preferably 100mg～3.5g/ days, more preferably 200mg～3.5g/ days, more preferably in the scope of 350mg～3.5g/ days.For " cow's milk phosphatide the concentrate " (choline that contains about 5 % by weight.85 % by weight lipids, 10 % by weight ash contents, 4 % by weight carbohydrate, and 1 % by weight moisture) intake, 1.4g～75g/ days, preferably 2.4g～75g/ days, more preferably 4.8g～75g/ days, be more preferably desirable (American Journal of Clinical Nutrition (U.S.'s clinical nutriology magazine) 2005 in the scope of 7.5g～75g/ days, the 82nd volume, 111-117 page; American Journal of Clinical Nutrition (U.S.'s clinical nutriology magazine) 2006, the 83 volumes, 905-911 page; European Journal of Nutrition (European nutrition magazine), 2007, the 46 volumes, 300-306 page, dietary reference is taken in, the 411st page).
Embodiment
{ the embodiment 1} pregnancy period is taken in the impact of cow's milk phosphatide
Experimental technique
In this experiment, rat is divided into four groups, every group of eight rats, point 4 raisings.When experiment starts, rat body weight scope is 155g～165g, and while completing experiment, (gestational period) rat body weight scope is 240g～290g.Now, every group of body weight do not have notable difference.
(1) make 9 week age female Wistar rats freely absorb low vitagen (low vitagen: remove vitamin B2, folic acid, cobalamin and lipotropin from AIN93G vitamin compound) or control Food (control group: AIN93G) 1 week.(table 1)
(2) make female Wistar rats mating in 10 week age.
(3) same day that will confirm mating (plug) was as pregnant 0 day.Every group is freely absorbed test food (AIN93G, low vitagen, low vitagen+cow's milk phosphatide (2.6 % by weight; Content of choline is approximately 40mg/g), low vitagen+lipotropin (0.25 % by weight)).Freely absorb test food until pregnant 20 days.It should be noted that, in low vitagen+cow's milk phosphatide, low vitagen+lipotropin and AIN93G, choline concentration is 0.1 % by weight.
In the time of pregnant the 20th day, by the about 0.3mL of venous blood collection, open abdomen, then taking-up tire mouse measures the body weight of tire mouse.It should be noted that, conventionally the tire mouse number of same abdomen is defined as 12+/-3 (eliminating exceeds the rat of this number) organize between contrast.When statistical analysis, use Statview (SAS company system) one-way analysis of variance to carry out (Post-hoc:Scheffe) check of multiple ratio.
[table 1]
*so-called " the low vegetarian diet mixed vitamin of supporting one's family " refers to the mixed vitamin preparing by remove vitamin B2, cobalamin, folic acid from AIN93G mixed vitamin.
Experimental result
Due to the low vitagen of picked-up, so tire mouse weight loss (Fig. 1).But because picked-up has added the low vitagen of cow's milk phosphatide, so tire mouse body weight improves, body weight has the tendency (Fig. 1 and table 2) of increase.
[table 2]
| Tire mouse body weight [g] | Standard deviation [g] | |
| Control group (n=68) | 3.156 | 0.288 |
| Low vitagen group (n=67) | 3.000 | 0.258 |
| Low vitagen+lipotropin group (n=70) | 3.068 | 0.217 |
| Low vitagen+cow's milk phosphatide group (n=34) | 3.199 | 0.249 |
It is essential to development of fetus that this experiment shows to absorb vitamin.Further show to absorb cow's milk phosphatide and can improve the fetal hypoplasia causing owing to being deficient in vitamin.
utilizability in industry
Pregnant drug thing, special used food or the dietary supplement performance of the present application can prevent the excellent effect that birth weight reduces.Therefore, described pregnant drug thing, special used food or dietary supplement, can be used for medicine or food manufacturing industry.
All publications cited herein, patent and patent application are all introduced into this description as reference.
Claims (8)
1. from the phosphatide of cow's milk, in preparation, prevent the application in pregnant drug thing that neonatal birth weight that pregnant woman produces reduces, described pregnant woman is insufficient to the picked-up of Cobastab and folic acid.
2. application as claimed in claim 1, wherein, contains sphingomyelins and/or phosphatid ylcholine from the phosphatide of cow's milk.
3. application as claimed in claim 1, wherein, the content of choline is at least 60mg/ days.
4. application as claimed in claim 2, wherein, the content of choline is at least 60mg/ days.
5. the pregnant woman who prevents in preparation the risk that neonatal birth weight that pregnant woman produces reduces from the phosphatide of cow's milk is with the application in special purposes food or dietary supplement, and described pregnant woman is insufficient to the picked-up of Cobastab and folic acid.
6. application as claimed in claim 5, wherein, contains sphingomyelins and/or phosphatid ylcholine from the phosphatide of cow's milk.
7. the application as described in claim 5 or 6, wherein, the content of choline is at least 60mg/ days.
From the phosphatide of cow's milk preparation prevent risk that neonatal birth weight reduces for modulating the application of pregnant woman with the food additives of special purposes food or dietary supplement, described pregnant woman is insufficient to the picked-up of Cobastab and folic acid.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009143615 | 2009-06-16 | ||
| JP2009-143615 | 2009-06-16 | ||
| PCT/JP2010/003959 WO2010146831A1 (en) | 2009-06-16 | 2010-06-15 | Prenatal milk-derived composition for preventing the risk of low birthweight of newborns |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102802442A CN102802442A (en) | 2012-11-28 |
| CN102802442B true CN102802442B (en) | 2014-05-07 |
Family
ID=42953864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080026600.5A Active CN102802442B (en) | 2009-06-16 | 2010-06-15 | Prenatal milk-derived composition for preventing the risk of low birthweight of newborns |
Country Status (5)
| Country | Link |
|---|---|
| JP (2) | JP6043064B2 (en) |
| CN (1) | CN102802442B (en) |
| HK (1) | HK1175665A1 (en) |
| TW (1) | TWI528904B (en) |
| WO (1) | WO2010146831A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016535734A (en) * | 2013-10-21 | 2016-11-17 | エンザイモテック リミテッド | Composition comprising choline and derivatives thereof, use and preparation method thereof |
| CN108057134B (en) * | 2017-12-26 | 2020-12-01 | 湖北回盛生物科技有限公司 | Dairy cow midwifery lubricant and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008081934A1 (en) * | 2006-12-28 | 2008-07-10 | Meiji Dairies Corporation | Agent for facilitating the development of brain in infant comprising milk-derived phospholipid and food composition comprising the same |
| CN101427784A (en) * | 2008-07-09 | 2009-05-13 | 内蒙古蒙牛乳业（集团）股份有限公司 | Liquid milk for pregnant and ylying-in woman with additive lecithin and method of producing the same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002512047A (en) | 1998-04-21 | 2002-04-23 | インターリューキン ジェネティックス インコーポレイテッド | Fetal testing to predict low birth weight |
| JP3195594B2 (en) * | 1999-11-02 | 2001-08-06 | 明治乳業株式会社 | A food composition containing a milk-derived phospholipid. |
| JP2002226394A (en) | 2001-02-01 | 2002-08-14 | Meiji Milk Prod Co Ltd | Lipid metabolism improving composition |
| JP5300186B2 (en) * | 2006-08-23 | 2013-09-25 | 株式会社明治 | Milk-derived composition for pregnant women that suppresses increase in homocysteine concentration in blood |
| JP2009143615A (en) | 2007-12-17 | 2009-07-02 | Oji Paper Co Ltd | Packaging vessel for powder detergent |
-
2010
- 2010-06-15 CN CN201080026600.5A patent/CN102802442B/en active Active
- 2010-06-15 TW TW099119530A patent/TWI528904B/en active
- 2010-06-15 JP JP2011548707A patent/JP6043064B2/en active Active
- 2010-06-15 WO PCT/JP2010/003959 patent/WO2010146831A1/en active Application Filing
-
2013
- 2013-03-11 HK HK13103020.3A patent/HK1175665A1/en unknown
-
2016
- 2016-07-19 JP JP2016141636A patent/JP6147900B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008081934A1 (en) * | 2006-12-28 | 2008-07-10 | Meiji Dairies Corporation | Agent for facilitating the development of brain in infant comprising milk-derived phospholipid and food composition comprising the same |
| CN101427784A (en) * | 2008-07-09 | 2009-05-13 | 内蒙古蒙牛乳业（集团）股份有限公司 | Liquid milk for pregnant and ylying-in woman with additive lecithin and method of producing the same |
Non-Patent Citations (1)
| Title |
|---|
| Yesim Ozarda Ilcol et al.Choline status in newborns，infants，children，breast-feeding women，breast-fed infants and human breast milk.《Journal of Nutritional Biochemistry》.2005,第16卷 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6147900B2 (en) | 2017-06-14 |
| WO2010146831A1 (en) | 2010-12-23 |
| TW201103443A (en) | 2011-02-01 |
| JP2016185985A (en) | 2016-10-27 |
| TWI528904B (en) | 2016-04-11 |
| HK1175665A1 (en) | 2013-07-12 |
| CN102802442A (en) | 2012-11-28 |
| JP2012530046A (en) | 2012-11-29 |
| JP6043064B2 (en) | 2016-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sharma et al. | Anemia in pregnancy | |
| RU2375079C2 (en) | Polyvitaminic and mineral food additives | |
| CN105581302B (en) | Jelly for providing energy required by parturient childbirth and preparation method thereof | |
| CN106983136A (en) | A kind of puerperium conditioning tailored version clinical nutrition formula and preparation method thereof | |
| KR20080030633A (en) | Method of treatment or management of stress | |
| JP6483024B2 (en) | Composition | |
| WO2018077276A1 (en) | Immunity-enhancing composition and preparation method therefor | |
| JP7104032B2 (en) | Protection of water-soluble tomato extract against adverse effects of air pollution | |
| CN102802442B (en) | Prenatal milk-derived composition for preventing the risk of low birthweight of newborns | |
| TW201332555A (en) | Use of specific carbohydrate systems during pregnancy for reducing adverse health effects later in life in offspring | |
| CN107624068B (en) | Compositions comprising cinnamaldehyde and zinc and methods of using such compositions | |
| PT2908828T (en) | Galactagogue compositions based on phosphatidylserine | |
| JP3433917B2 (en) | Nutritional composition for enhancing body protein accumulation efficiency | |
| US20230027781A1 (en) | Prenatal Dosage Forms, Methods of Administration and Kits Thereof | |
| WO2017036971A1 (en) | Prophylaxis of hypertension and cardiovascular diseases | |
| Reardon et al. | PHYSIOLOGICAL DEVIATIONS OF THE PREMATURE INFANT: With Summary of Principles of Care | |
| JP5300186B2 (en) | Milk-derived composition for pregnant women that suppresses increase in homocysteine concentration in blood | |
| AU2011101216A4 (en) | Chocolate bars | |
| CN107950849A (en) | A kind of puerpera's electrolyte energy drink and its enter quantity management method | |
| Hamed et al. | Overview of the Updates in Nutrient Profiles, Types, Indications and Side Effects of Infant Formula | |
| NASMI | DEVELOPMENT OF MALT POWDER–IRON–FOLIC ACID RICH PRODUCT | |
| CA3175207A1 (en) | Sleep quality improver | |
| Thompson | Vitamins, minerals and supplements 5: overview of vitamin C | |
| Suprabha | Role of Madhuraushadha Siddha Avaleha as Garbhini Rasayana in the 6 th and 7 th Month of Pregnancy | |
| Hoover et al. | Drug-Nutrient Interaction Considerations in Pregnancy and Lactation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1175665 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1175665 Country of ref document: HK |